Pakistan Pharmaceutical: Shines with outperformance; triggers ahead – By JS Research
Dec 23 2024
JS Global Capital
- Pharma sector has outperformed the KSE-100 by 118% CYTD, after underperforming the market for 3-consecutive years Despite the rally, the sector remains attractive due to growing profitability driven by higher margins from deregulated nonessential drugs, recurring earnings growth, new product launches, strategic acquisitions, and expansion into new markets.
- We highlight, our sample of listed Pharma sector has reported net sales of Rs295bn during the past 4-quarters, arriving at a growth of 17%YoY mainly on account of higher prices post one-off increase granted during last year, wherein deregulation of non-essential medicines also contributed to the same.
- The sector continues its growth trajectory with the industry reaching Rs982bn in value terms as of Oct-2024 (moving annual total), posting a growth of 22% YoY and a 4-year value CAGR of 19%. AGP remains our top pick in Pakistan Pharma listed space with a Dec-2025 TP of Rs250, offering an upside of 53%.